📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 13:46
225 analysed today
FollowTelegram
225
Today
149,626
All-time analysed
42,906
Positive
6,661
Negative
91,382
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
18 announcements match the current filters (relevance ≥ 5).
Entero Q1 FY27 Concall: Revenue rises 38.2% YoY to ₹1,940 Cr; EBITDA margin touches 5%
Entero Healthcare Solutions reported a 38.2% YoY revenue growth to ₹1,940 Cr in Q1 FY27, led by 17.8% organic growth and 20.4% inorganic contribution from prior acquisitions. Operating EBITDA surged 94% YoY with margins expanding 143 bps to 5.0%, achieving the management's full-year FY27 margin target in the first quarter itself. PAT increased 72% YoY to ₹52 Cr (PAT attributable to owners stood at ₹38 Cr), aided by scale-led procurement efficiencies and higher-margin MedTech expansion. Management reaffirmed its FY27 guidance of ~23% consolidated revenue growth and expects MedTech revenue to cross ₹1,000 Cr organically.
Confidence: HIGH
What changedFiling of the official transcript for the Q1 FY27 earnings call outlining detailed operating metrics, margin drivers, and FY27 guidance.
Why it mattersDemonstrates operating leverage and working capital optimization across Entero's 138-warehouse network as higher-margin MedTech and retail distribution scale up.
Q1 FY27 Revenue: INR 1,940 croresYoY Revenue Growth: 38.2%Q1 FY27 EBITDA Margin: 5.0%Q1 FY27 PAT: INR 52 croresNet Working Capital Days: 61 daysFY27 MedTech Revenue Target: > INR 1,000 crores
📅 Short termPositive sentiment supported by healthy top-line expansion, margin achievement, and stable working capital days.
📈 Long termThe company's expansion into higher-margin MedTech products and market share consolidation in pharma distribution support long-term ROCE expansion.
⚠ Risk flags
- Significant non-controlling interest (₹14 Cr in Q1) due to partially owned subsidiaries with pending buyout options
- Complexity of inventory and working capital management across 138 warehouses
Key Highlights
Consolidated revenue climbed 38.2% YoY (40.0% like-for-like) to ₹1,940 Cr in Q1 FY27.
EBITDA rose 94% YoY to achieve a 5.0% margin, up 143 bps YoY, meeting the full-year target early.
Net profit after tax grew 72% YoY to ₹52 Cr, with minority interest accounting for ₹14 Cr.
Working capital cycle improved to 61 days from 66 days YoY; ROCE expanded to 21.1% from 11.5% YoY.
MedTech revenue is projected to exceed ₹1,000 Cr organically during FY27.
👀 What to Watch
Track whether the 5% EBITDA margin is sustained through upcoming quarters and monitor organic traction in the higher-margin MedTech segment toward the ₹1,000 Cr milestone.
38% Revenue Growth and 94% EBITDA Surge in Q1 FY27; ROCE Doubles to 21.1%
Entero Healthcare reported a strong start to FY27 with consolidated revenue reaching Rs 1,940.5 Cr, a 38% YoY increase. Operational efficiency improved significantly as EBITDA grew 94% to Rs 97 Cr, with margins expanding 143 bps to 5.0%. Return ratios showed marked improvement, with ROCE nearly doubling to 21.1% and ROE reaching 20.4%. The company maintained its growth momentum with organic growth of 17.8%, outperforming the Indian Pharmaceutical Market (IPM) growth of 12%.
Confidence: HIGH
What changedEntero has demonstrated a sharp improvement in profitability and capital efficiency (ROCE/ROE) while maintaining high double-digit organic growth.
Why it mattersThe results validate the scalability of Entero's distribution model and its successful pivot toward higher-margin MedTech categories, which now command a significant portion of the business.
Q1 Revenue: Rs 1,940.5 CrRevenue vs TTM: ~38.9%EBITDA Margin: 5.0%ROCE: 21.1%MedTech FY27 Target: >Rs 1,000 Cr
📅 Short termPositive sentiment is expected as the company delivers on its growth guidance with substantial margin expansion and improved return ratios.
📈 Long termThe structural shift toward higher-margin MedTech and the consolidation of the fragmented pharma distribution market positions the company for steady long-term growth.
⚠ Risk flags
- Integration risks associated with 51+ historical acquisitions
- Low operating margins (5%) inherent to the distribution and trading industry
Key Highlights
Consolidated revenue grew 38% YoY to Rs 1,940.5 Cr, contributing ~39% of the previous TTM revenue in a single quarter
EBITDA margins expanded by 143 bps YoY to reach 5.0%, driven by higher-margin MedTech and trade generics
Return on Capital Employed (ROCE) improved significantly to 21.1% from 11.5% in Q1 FY26
Organic revenue growth of 17.8% outperformed the Indian Pharmaceutical Market (IPM) growth of 12%
Net Working Capital (NWC) days improved to 61 days from 66 days in the previous year
👀 What to Watch
Monitor the company's ability to sustain 5%+ EBITDA margins and the execution of its MedTech segment, which is targeted to exceed Rs 1,000 Cr in revenue for FY27.
Q1 Standalone PAT Falls 50% YoY to ₹3.46 Cr; Revenue at ₹83.27 Cr
Entero Healthcare reported a weak set of standalone results for Q1 FY27, with net profit dropping 50.3% YoY to ₹3.46 Cr from ₹6.96 Cr. While standalone revenue from operations grew 4.9% YoY to ₹83.27 Cr, profitability was hit by a 120% surge in finance costs (₹5.74 Cr vs ₹2.60 Cr) and a decline in other income. The company continues its strategy of supporting subsidiaries, subscribing to Optionally Convertible Debentures (OCDs) in four entities during the quarter. Board committees were also reconstituted following the retirement of an independent director.
Confidence: HIGH
What changedEntero reported its Q1 FY27 standalone financials showing margin pressure and announced a transition in its board committee leadership effective August 25, 2026.
Why it mattersThe sharp rise in standalone finance costs and the drop in standalone PAT suggest increased debt servicing or internal funding costs at the parent level, which warrants monitoring despite the company's aggressive acquisition strategy.
Standalone Revenue (Q1 FY27): ₹83.27 CrStandalone PAT (Q1 FY27): ₹3.46 CrYoY PAT Growth: -50.3%Finance Costs (Q1 FY27): ₹5.74 CrStandalone Revenue vs TTM Cons. Revenue: ~1.7%
📅 Short termThe stock may see negative sentiment in the short term due to the significant drop in standalone profitability and rising interest expenses.
📈 Long termThe long-term outlook depends on the successful integration and margin accretion of the numerous subsidiaries (48+ listed) and the achievement of the 30% revenue growth guidance.
⚠ Risk flags
- Sharp increase in finance costs
- Significant decline in standalone net profit
- High complexity with 48+ subsidiary entities
Key Highlights
Standalone Revenue from operations increased 4.9% YoY to ₹83.27 Cr.
Standalone Net Profit declined 50.3% YoY to ₹3.46 Cr from ₹6.96 Cr in the year-ago period.
Finance costs surged by 120.7% YoY to ₹5.74 Cr, impacting the bottom line.
Subscribed to OCDs in 4 subsidiaries including Avenues Pharma and Sri Parshva Pharma.
Allotted 12,135 equity shares under ESOP at a premium of ₹794 per share.
👀 What to Watch
Investors should focus on the consolidated financial performance, as standalone revenue represents less than 2% of the group's TTM consolidated revenue, indicating most operations reside in subsidiaries.
Entero Reports FY26 Revenue of ₹6,591 Cr, Up 29.3%; MedTech Target >₹1,000 Cr for FY27
Entero Healthcare has released its FY25-26 Annual Report, reporting a 29.3% revenue growth to ₹6,591 crore, significantly outperforming the broader pharmaceutical market. EBITDA grew 55% YoY to ₹266 crore, with margins expanding from 3.4% to 4.0% due to operating leverage and a better product mix. A key milestone was achieved with positive operating cash flow of ₹96 crore, while ROCE improved to 14.6%. The company is now targeting over ₹1,000 crore in annualized revenue from its MedTech segment in FY27.
Confidence: HIGH
What changedThe company has transitioned from a loss-making/low-margin phase to generating positive operating cash flow (₹96 Cr) and significantly higher ROCE (14.6%).
Why it mattersThe shift toward MedTech and higher-value distribution is improving the margin profile (Gross Margin up 78 bps to 10.3%), which is critical for a low-margin trading business.
FY26 Revenue: ₹6,591 croreFY26 EBITDA: ₹266 croreOperating Cash Flow: ₹96 croreFY26 ROCE: 14.6%MedTech FY27 Target: >₹1,000 croreRevenue Growth vs IPM: 2.1x (29.3% vs ~14%)
📅 Short termThe stock may see positive sentiment as the annual report confirms strong execution on growth and margin expansion targets.
📈 Long termIf Entero successfully scales its MedTech platform to ₹1,000 Cr+, it could structurally re-rate the business from a pure pharma distributor to a high-value healthcare platform.
⚠ Risk flags
- Integration risks of multiple acquisitions
- High inventory complexity across 136 warehouses
- Working capital management in a fragmented market
Key Highlights
FY26 Revenue reached ₹6,591 crore, representing 29.3% reported growth and 31.5% like-for-like growth
EBITDA increased by 55% to ₹266 crore, with EBITDA margins improving 60 bps to 4.0%
Achieved ₹96 crore in operating cash flow, a significant milestone for the company
MedTech business expected to contribute >₹1,000 crore of annualized revenue in FY27
Network expanded to 136 warehouses covering 523 districts and 105,300+ retail pharmacy customers
👀 What to Watch
Watch for the upcoming AGM on August 19, 2026, and monitor the quarterly progress of the MedTech segment to see if it hits the ₹1,000 crore annualized run rate.
Entero Reports FY26 Revenue of ₹6,591 Cr (Up 29.3%); AGM Scheduled for August 19
Entero Healthcare has released its FY25-26 Annual Report and scheduled its 8th AGM for August 19, 2026. The company reported a strong FY26 performance with revenue growing 29.3% to ₹6,591 crore, significantly outperforming the broader pharmaceutical market. Profitability showed marked improvement with EBITDA rising 55% to ₹266 crore and EBITDA margins expanding to 4.0%. A key strategic shift is the expansion into the MedTech segment, which is projected to contribute over ₹1,000 crore in annualized revenue by FY27.
Confidence: HIGH
What changedThe company has formalized its annual reporting for FY26 and set the timeline for shareholder voting and the annual general meeting.
Why it mattersThe report confirms Entero's successful transition from a pure-play pharma distributor to an integrated healthcare platform, showing improved margins and positive operating cash flow despite aggressive inorganic expansion.
FY26 Revenue: ₹6,591 croreEBITDA Growth: 55%FY27 MedTech Revenue Target: >₹1,000 croreOperating Cash Flow: ₹96 croreROCE: 14.6%Warehouse Count: 136
📅 Short termThe stock may see positive sentiment as the market digests the strong FY26 growth figures and the positive operating cash flow milestone reported in the annual report.
📈 Long termThe company is structurally positioning itself in the higher-margin MedTech and trade generics space, which could lead to sustained margin expansion beyond the current 4% EBITDA level.
⚠ Risk flags
- Integration risks associated with rapid inorganic acquisitions
- High industry fragmentation
- Working capital management across 100+ warehouses
Key Highlights
FY26 Revenue reached ₹6,591 crore, representing 29.3% reported growth and 31.5% like-for-like growth
EBITDA increased by 55% to ₹266 crore, with margins improving from 3.4% to 4.0%
MedTech segment expected to contribute more than ₹1,000 crore of annualized revenue in FY27
Achieved ₹96 crore in operating cash flow, a significant milestone for the company
Return on Capital Employed (ROCE) strengthened to 14.6% with ROE improving to 12.5%
👀 What to Watch
Investors should focus on the upcoming AGM for management commentary regarding the integration of recent MedTech acquisitions and the sustainability of the 30% revenue growth guidance for FY27.
Entero Healthcare FY26 Revenue Jumps 31.5% to ₹6,591 Cr; Targets 5% EBITDA Margin in FY27
Entero Healthcare Solutions reported a robust FY26 with like-for-like revenue growth of 31.5% to ₹6,591 crores, meeting its guidance. EBITDA margins improved to 4% for the full year, driven by procurement efficiencies and a better product mix, while Q4 margins reached 4.5%. The company successfully integrated 7 acquisitions, scaling its MedTech segment to over ₹1,000 crores in annualized revenue. Management has issued a positive outlook for FY27, targeting 23% organic revenue growth and a further margin expansion to 5%.
Key Highlights
FY26 revenue grew 31.5% like-for-like to ₹6,591 crores, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.6x.
EBITDA margin expanded by 67 bps YoY to 4% for FY26, with Q4 FY26 EBITDA growing 76% YoY to ₹86 crores.
MedTech segment now contributes over ₹1,000 crores in annualized revenue following strategic acquisitions in diagnostics and cardiology.
Return on Capital Employed (ROCE) improved significantly to 18.4% in Q4 FY26 from 14.8% in the previous quarter.
Management guided for 23% organic revenue growth and 5% EBITDA margins for FY27, with a focus on 50% EBITDA-to-cash conversion.
👀 What to Watch
Investors should view the consistent margin expansion and successful acquisition integration as a sign of operational maturity. Monitor the normalization of minority interests in FY27, which is expected to drop to 25-27% of PAT from the current 38%.
Entero Healthcare Clarifies INR 114 Mn One-Off Impact and Minority Interest Rise in Q4 FY26
Entero Healthcare Solutions has issued a clarification regarding its Q4 FY26 financial results to address investor concerns over modest profit growth and rising minority interests. The company noted that profit attributable to owners was impacted by one-off items totaling INR 114 million, related to business contract closures and higher provisioning. Furthermore, the increase in non-controlling interest is due to the acquisition of a 51.51% stake in Anand Chemiceutics Private Limited during the quarter. This clarification aims to separate non-recurring costs from the company's core operational performance.
Key Highlights
One-off costs of INR 114 million impacted net profit due to contract closures and provisioning charges.
Non-controlling interest rose following the acquisition of a 51.51% stake in Anand Chemiceutics Private Limited.
The profit drag originated specifically from standalone financials and wholly owned subsidiaries.
Management maintains that the company experienced operational growth during the quarter despite these accounting adjustments.
👀 What to Watch
Investors should add back the INR 114 million one-off charge to evaluate the company's underlying operational run-rate. Monitor the margin profile of the newly acquired Anand Chemiceutics to see if it remains accretive to the consolidated bottom line.
Entero Healthcare to Host Q4FY26 Earnings Call on May 26, 2026
Entero Healthcare Solutions Limited has scheduled its earnings conference call to discuss the audited financial results for the quarter and full year ended March 31, 2026. The call is set for Tuesday, May 26, 2026, at 12:00 PM IST and will be hosted by DAM Capital Advisors. Top management, including the MD & CEO, COO, and Group CFO, will be present to interact with analysts and institutional investors regarding the company's performance.
Key Highlights
Earnings call scheduled for May 26, 2026, at 12:00 PM IST regarding Q4 and FY26 results.
Management participants include MD & CEO Prabhat Agrawal and Group CFO Balakrishnan Natesan Kaushik.
The call is hosted by DAM Capital Advisors Ltd with universal access numbers +91 22 6280 1384 and +91 22 7115 8285.
International dial-in timings provided for Hong Kong, Singapore, UK, and USA markets.
👀 What to Watch
Investors should monitor the call for management commentary on revenue growth, margin expansion, and the progress of their inorganic growth strategy in the healthcare distribution sector.
Entero Healthcare's Subsidiary Rada Medisolutions Completes Merger of Two Pharma Distributors
Entero Healthcare Solutions has received regulatory approval for the amalgamation of Chethana Pharma Distributors and CPD Pharma into Rada Medisolutions Private Limited. Both merging entities were wholly-owned subsidiaries of Rada Medisolutions, which is a key part of the Entero group. The merger is effective retrospectively from the Appointed Date of April 15, 2025, following a confirmation order from the Ministry of Corporate Affairs. This internal restructuring is designed to simplify the group's corporate structure and reduce administrative and compliance costs.
Key Highlights
Merger of Chethana Pharma (Paid-up capital ₹30 Lakh) and CPD Pharma (Paid-up capital ₹25 Lakh) into Rada Medisolutions approved.
The amalgamation was processed via the Fast-track route under Section 233 of the Companies Act, 2013.
The scheme is effective from April 15, 2025, as per the Regional Director's confirmation order dated April 17, 2026.
Aims to achieve operational efficiencies and economies of scale by eliminating corporate redundancies in pharmaceutical distribution.
Post-merger, the transferee company Rada Medisolutions maintains an authorized share capital of ₹80 Lakh.
👀 What to Watch
This is a positive internal restructuring that should lead to better margins through cost optimization. Investors should monitor if these efficiencies reflect in the upcoming quarterly consolidated financial statements.
Entero Healthcare Q3 FY26: Revenue Up 26% YoY to ₹1,707 Cr, EBITDA Margins Expand to 4%
Entero Healthcare reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,707 crores, driven by 17.1% organic growth. EBITDA margins expanded by 30 bps to 4%, while adjusted PAT rose 36% to ₹40 crores after accounting for a one-time labor code impact. The company successfully closed several MedTech acquisitions, projecting this segment's annualized revenue to exceed ₹1,000 crores. Management remains confident in achieving its ₹100 crore operating cash flow target for FY26.
Key Highlights
Revenue grew 26% YoY to ₹1,707 crores with a record 17.1% organic growth rate.
EBITDA increased 36% YoY to ₹68 crores, achieving a 4% margin.
MedTech acquisitions completed; segment revenue expected to surpass ₹1,000 crores with 50-75 bps EBITDA margin accretion.
Net Working Capital improved to 61 days (like-to-like), generating ₹49 crores in operating cash flow this quarter.
Adjusted PAT grew 36% YoY to ₹40 crores, excluding a ₹6.1 crore one-off labor code impact.
👀 What to Watch
Investors should monitor the integration of recent MedTech acquisitions and the company's ability to meet its ₹100 crore operating cash flow guidance in Q4. The shift towards higher-margin MedTech and improved working capital efficiency are positive long-term indicators.
Entero Healthcare Q3 FY26 Revenue at ₹1,067M; PAT Impacted by ₹44.8M Exceptional Item
Entero Healthcare reported a revenue of ₹1,067.35 million for the quarter ended December 31, 2025, showing growth over the previous quarter's ₹832.21 million. Net profit for the quarter stood at ₹8.05 million, significantly impacted by a one-time exceptional charge of ₹44.87 million related to the implementation of New Labour Codes. The company has successfully utilized its total IPO proceeds of ₹5,548 million for debt repayment, working capital, and inorganic growth. Multiple acquisitions were completed during the period, including Ramson Medical and Sri RK Pharma, to strengthen its distribution network.
Key Highlights
Revenue from operations grew to ₹1,067.35 million in Q3 FY26 compared to ₹832.21 million in Q2 FY26.
Profit After Tax (PAT) for Q3 FY26 was ₹8.05 million, following a ₹44.87 million exceptional item for labor code compliance.
The company fully utilized ₹5,548 million of IPO proceeds, with ₹1,425 million used for debt repayment.
Aggressive inorganic expansion continued with the acquisition of six entities including Ramson Medical and Bio-side Technologies.
9M FY26 PAT stood at ₹134.59 million on a total income of ₹3,430.76 million.
👀 What to Watch
Investors should monitor the integration of recent acquisitions and the impact on margins once one-time labor code costs are absorbed. The revenue growth trend is positive, but bottom-line consistency is key for long-term valuation.
Entero Healthcare Q3 Standalone PAT Drops to ₹8.06M; Cancels Two Acquisitions
Entero Healthcare reported a standalone revenue of ₹1,067.36 million for Q3 FY26, showing growth from ₹832.21 million in the previous quarter. However, Standalone Profit After Tax (PAT) plummeted to ₹8.06 million from ₹107.83 million in the same quarter last year, a significant year-on-year decline. This drop was exacerbated by a ₹44.97 million exceptional item related to incremental liabilities from New Labour Codes. Additionally, the company cancelled the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons.
Key Highlights
Standalone Revenue from operations stood at ₹1,067.36 million for Q3 FY26 compared to ₹1,011.52 million YoY.
Net Profit (PAT) fell sharply to ₹8.06 million from ₹107.83 million in the corresponding quarter of the previous year.
Recognized an exceptional expense of ₹44.97 million (₹33.65 million net of tax) due to New Labour Code compliance.
Cancelled two planned acquisitions (Khera Medisolutions and AV Medisolutions) previously announced in 2025.
Board approved the grant of 5,000 fresh Employee Stock Options (ESOPs) under the 2023 plan.
👀 What to Watch
Investors should monitor the company's ability to maintain margins following the sharp decline in profitability and the impact of regulatory labor costs. The cancellation of two acquisitions may signal a more selective approach to inorganic growth or potential valuation hurdles.
Entero Healthcare Q3 Revenue Up 25.6% to ₹1,707 Cr; Achieves Positive Operating Cash Flow
Entero Healthcare reported a strong Q3FY26 with revenue growing 25.6% YoY to ₹1,706.5 crore, driven by 17.1% organic like-for-like growth. The company achieved a significant milestone by generating positive operating cash flow of ₹49 crore during the quarter, reversing previous negative trends. EBITDA margins improved by 29 bps to 4.0%, while adjusted PAT (excluding a one-off labor code impact) rose 36% to ₹40 crore. Management is aggressively expanding into the high-margin MedTech segment, which is projected to exceed ₹1,000 crore in revenue next fiscal year.
Key Highlights
Reported revenue grew 25.6% YoY to ₹1,706.5 Cr, with organic LFL growth outperforming the industry at 17.1%.
EBITDA increased by 35.5% YoY to ₹67.8 Cr, with margins expanding to 4.0% from 3.7% YoY.
Generated positive Operating Cash Flow of ₹49 Cr in Q3, a sharp turnaround from negative ₹10.3 Cr in Q2FY26.
Completed 7 acquisitions year-to-date, with a strategic focus on the MedTech segment to drive margin expansion.
Net Working Capital (NWC) days improved to 61 on a like-for-like basis compared to 63 in the previous quarter.
👀 What to Watch
Investors should take note of the company's successful transition to positive operating cash flow and its margin-accretive acquisition strategy in the MedTech space. The stock remains an attractive growth play as it continues to gain market share and consolidate the fragmented healthcare distribution industry.
Entero Healthcare Q3 PAT Drops to ₹8.06M; Cancels Two Acquisitions & Grants 5,000 ESOPs
Entero Healthcare reported a sharp decline in standalone net profit to ₹8.06 million for Q3 FY26, down from ₹107.83 million YoY, largely due to a ₹44.97 million exceptional charge for new labour code compliance. Revenue from operations grew modestly to ₹1,067.36 million from ₹1,011.52 million in the year-ago period. Notably, the company has cancelled the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. The board also approved a small grant of 5,000 fresh ESOPs to employees.
Key Highlights
Standalone Net Profit fell over 92% YoY to ₹8.06 million in Q3 FY26.
Recognized a one-time exceptional expense of ₹44.97 million related to New Labour Code liabilities.
Cancelled two previously announced acquisitions (Khera Medisolutions and AV Medisolutions) citing commercial reasons.
Standalone Revenue from operations increased by 5.5% YoY to ₹1,067.36 million.
Board approved the grant of 5,000 fresh Employee Stock Options under the 2023 Plan.
👀 What to Watch
Investors should exercise caution as the significant drop in profitability and the cancellation of planned acquisitions suggest potential headwinds in growth and margins. Monitor management's outlook on inorganic growth strategy and the impact of rising employee benefit costs.
Entero Healthcare Approves Q3 Results, Cancels Two Acquisitions, and Grants 5,000 ESOPs
Entero Healthcare Solutions approved its Q3 and nine-month financial results for the period ending December 31, 2025. In a significant strategic shift, the company announced the cancellation of the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. Additionally, the board approved the grant of 5,000 ESOPs to employees at an exercise price of INR 804 per share. The company noted a temporary technical delay in generating the UDIN for the consolidated financial results due to portal maintenance.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Cancelled the acquisitions of Khera Medisolutions and AV Medisolutions, previously announced in 2025.
Granted 5,000 ESOPs under the Entero Employee Stock Option Plan 2023 at an exercise price of INR 804.
ESOPs have a vesting period ranging from 1 to 4 years and an exercise period of 8 years from vesting.
Statutory auditors reported a technical error in UDIN generation for consolidated results, to be updated later.
👀 What to Watch
Investors should review the detailed Q3 financial performance and seek management commentary regarding the cancellation of the two acquisitions to understand the impact on the company's inorganic growth strategy.
Entero Healthcare Q3 Results Approved; Cancels Two Acquisitions; Grants 5,000 ESOPs
Entero Healthcare's board approved the financial results for the quarter and nine months ended December 31, 2025. A significant strategic update includes the cancellation of the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. The board also approved the grant of 5,000 ESOPs to eligible employees at an exercise price of INR 804 per share. Additionally, the company noted a technical delay in generating the UDIN for consolidated results due to auditor portal maintenance.
Key Highlights
Approved standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
Cancelled the proposed acquisitions of Khera Medisolutions Private Limited and AV Medisolutions Private Limited.
Granted 5,000 Employee Stock Options (ESOPs) at an exercise price of INR 804 per share.
ESOPs have a vesting period of 1 to 4 years and an exercise period of 8 years from vesting.
Statutory auditors reported a temporary technical error in generating UDIN for consolidated results.
👀 What to Watch
Investors should closely examine the Q3 financial performance and seek management commentary regarding the 'commercial reasons' for cancelling the two previously announced acquisitions. Monitor the stock's reaction to the INR 804 ESOP exercise price relative to the current market price.
Entero Healthcare Completes 51.5% Stake Acquisition in Anand Chemiceutics
Entero Healthcare has successfully closed the acquisition of a 51.5% stake in Anand Chemiceutics, a prominent diagnostic and MedTech solutions provider. This acquisition significantly expands Entero's footprint in the diagnostic distribution space, adding a network of over 1,500 laboratories and hospitals. Management expects the MedTech segment to contribute more than INR 1,000 crore in annualized revenue during the next financial year. This move is a strategic step toward building an integrated healthcare supply chain platform in India.
Key Highlights
Acquired a 51.5% majority stake in Anand Chemiceutics, a diagnostic and MedTech specialist established in 2003.
The acquisition adds a customer service network of 1,500+ laboratories, hospitals, and government institutions.
MedTech segment is projected to generate over INR 1,000 crore in annualized revenue in the next financial year.
Expands capabilities into high-growth areas like advanced genomics and turnkey solutions for hospitals.
The deal leverages Entero's proprietary technology platform and distribution reach to scale the acquired business.
👀 What to Watch
Investors should monitor the integration of Anand Chemiceutics as it provides a significant revenue boost and entry into higher-margin diagnostic segments. The projected INR 1,000 crore revenue contribution makes this a key growth driver for the next fiscal year.
Entero Healthcare Completes Acquisition of 51.51% Stake in Anand Chemiceutics
Entero Healthcare Solutions Limited has successfully completed the acquisition of a 51.51% majority equity stake in Anand Chemiceutics Private Limited. This follows the initial announcement made on November 12, 2025, regarding the proposed transaction. The completion of this acquisition allows Entero to consolidate the financials of Anand Chemiceutics, supporting its inorganic growth strategy. This move strengthens the company's position in the healthcare distribution market.
Key Highlights
Acquired a majority equity stake of 51.51% in Anand Chemiceutics Private Limited.
The acquisition process was completed on February 07, 2026.
The transaction was previously disclosed on November 12, 2025.
The move aligns with SEBI Regulation 30 for material disclosures.
👀 What to Watch
Investors should monitor the upcoming quarterly results to evaluate the margin profile and revenue contribution of the newly acquired entity.
